However, the most efficient active targeting for combined nanomedicines in breast cancer was achieved by means of trastuzumab monoclonal antibodies (brand name Herceptin), targeting the human epidermal growth factor receptor 2 (HER2), which have been tested in vivo in orthotopic mouse cancers induced with TBNC 4T1 and HER2-positive SKBR3 cells. This evidence concerns the gene ERBB2 and breast carcinoma.